fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Acebutolol HCL

All products: general benefit

Apo-Acebutolol · DIN 02147610 · 200 mg · tablet

General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Apo-Acebutolol · DIN 02147610 Manufacturer: Apotex Inc.; listing date 1996-10-01 Daily cost (source): $0.5616 Health Canada: Marketed since 1995-12-31 · brand APO-ACEBUTOLOL · ATC C07AB04 ACEBUTOLOL · form Tablet · route Oral · ingredients ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 200 MG · company 4 mangos marketing inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Acebutolol: Formulary list price $0.28 per unit (the source does not state the unit; exact figure $0.2808). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02147610)

Source record
DIN 02147610: Apo-Acebutolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400085; group id 272; item number 0563; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2808; ministry $0.2808 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02147610 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17827
Interchangeable products
Sectral · DIN 01926551 · not recorded Teva-Acebutolol · DIN 02204525 · $0.2808
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (C07A, C07AB): coverage varies; not interchangeable

  • Atenolol (Apo-Atenol): general benefit
  • Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, not a benefit
  • Metoprolol (Lopresor SR): general benefit, not a benefit
  • Nebivolol (Bystolic): not a benefit
  • Nadolol (Corgard): general benefit, not a benefit
  • Propranolol (Inderal-LA): general benefit, not a benefit

3 more in the class list below

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:04 Cardiac Drugs

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 59 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph FELODIPINE · General benefit (10), Listed, not a benefit (2) 1 INDICATIONS PLENDIL (felodipine) is indicated for: • the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082730.PDF; date 2025-12-09; DIN 00851779; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. Treatment of mild to moderate hypertension: APO-ACEBUTOLOL is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be tried alone as an initial agent in those patients in whom, in the judgment of the physician, treatment should be started with a β-blocker rather than a diuretic. In patients with severe hypertension a β-adrenergic blocking agent may be used as part of a multiple drug regimen which would normally include a diuretic and a vasodilator. The combination of acebutolol with a diuretic or peripheral vasodilator has been found to be compatible and generally more effective than acebutolol alone. Limited experience with other antihypertensive agents has not shown evidence of incompatibility. APO-ACEBUTOLOL is not indicated in the emergency treatment of hypertensive crises. Geriatrics: Acebutolol has been used in the elderly without specific adjustment of dosage. APO-ACEBUTOLOL Product Monograph Page 3 of 34 Ho… https://pdf.hres.ca/dpd_pm/00047998.PDF PM date: October 24, 2018 Source product: APO-ACEBUTOLOL; DIN 02147602; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18